The OCMX™ is pleased to announce the listing of WoundNostics to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.
TORONTO, ON, December 20, 2021 /24-7PressRelease/ — Woundnostics Inc. is a Canadian company focused on developing novel wound care diagnostic tests. As innovators & researchers, we are now in the early stages of developing a “Point of Care” Diagnostic Test to determine the progress of wound healing.
The OCMX™ is pleased to announce the listing of WoundNostics to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.
The OCMX™ has spent considerable time completing its due diligence on WoundNostics and concluded that there is indeed a tremendous potential for this opportunity.
The OCMX™ noted that WoundNostics exhibits the main components of any solid opportunity, namely a strong management team, a great track record, and a number of key competitive advantages.
WHAT THEY DO
Dr. Stacey’s idea came to fruition with the science of biomarkers and the passion to find a way to measure wound progress without the traditional method of subjective observation & measurement. This research is the first of its kind world-wide. Through this work, Dr. Michael C. Stacey is ready to take this technology to the next step.
Picture a diagnostic point of care test at the bedside. A disposable test that can indicate a wound’s progress. This technology will enable a new paradigm of wound care that links healing status to therapies that impact the healing process. With a novel point of care wound fluid diagnostic, we can now determine if a wound is not healing and immediately change the treatment trajectory which will improve clinical efficacy, quality of life and the exponential costs to the health care system worldwide.
WHERE THEY ARE HEADED
Chronic wounds such as Diabetic Foot Ulcers and Venous Leg Ulcers dramatically impact quality of life, risk of infection and may even lead to amputation. The cost burden to health care is exponential and the reality that chronic wounds are on a dramatic increase worldwide, we need to support change in the assessment of wound healing.
Through research efforts in identifying a wound care diagnostic, evaluating wound healing status at the bedside is now achievable. As a result, the ability to modify your wound treatment and healing trajectory can be immediate. This will significantly enhance decision making of treatment options far more quickly compared to our current methodology of watching and measuring a wound’s progression. A life changing technology is about to transform wound care.
OPPORTUNITY HIGHLIGHTS
• Rapid Test Diagnostic in Wound Healing which is in high demand
• Research in humans has validated its accuracy
• We have created early adoption with an established advisory board of highly talented wound specialists in their field
• The market is in need due to high complication impact in patients with Chronic Wounds especially in the Diabetic market
• Sustainable business growth for the future
• Will have high margins from manufacturing volume
• High Growth Opportunity
MANAGEMENT TEAM
Dr. Michael C. Stacey, Founder & Chief Scientific Officer: Dr. Michael C. Stacey has a passion for chronic wound management and has been the principal researcher in the international field for over 30 years. As the inventor, Michael will lead this role with experience and expertise as he guides the success of this new technology. Transitioning from Perth Australia, Michael now lives in Canada and is the Chief Medical Officer and Executive VP Academics for Hamilton Health Sciences in the province of Ontario. He will maintain his integral role in research as he is the reason we are here today.
Marianne MacMillan, Chief Executive Officer: Marianne MacMillan has a strong leadership background with an infectious entrepreneurial spirit. Marianne has global expertise and experience as an executive in Medical Devices within the wound care industry for a number of years. Marianne has been successful in bringing new technologies globally into the market. Her success encompasses years of dedication to the Wound Care Industry. Pride in her work and passion will add great value to the next steps in commercializing Dr. Michael Stacey’s technology.
ABOUT THE OCMX™
The OCMX™ is changing how companies generate exposure in the financial marketplace and raise funds as we know it. The OCMX™ serves both public and private companies in need of market exposure during financial raises. It does this by way of connecting the relevant companies with financial institutions all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.
The OCMX™ connects investors and advisors directly with companies seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors.
The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.
Contact Us
The OCMX™
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: prosper@theocmx.com
WoundNostics gets listed on THE OCMX™
https://theocmx.com/marketplace/woundnostics/
—
For the original version of this press release, please visit 24-7PressRelease.com here
